logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5145.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5145.produseast1
Showing 1 - 15 of 15 Items
Showing 1 - 15 of 15 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Commentary

Disease-specific differences in pharmacokinetics of paromomycin and miltefosine between post-kala-azar dermal leishmaniasis and visceral leishmaniasis patients in eastern Africa

Chu WY, Verrest L, Younis BM, Musa AM, Mbui J,  et al.
2024-12-16 • Journal of Infectious Diseases
2024-12-16 • Journal of Infectious Diseases

Treatment regimens for post-kala-azar dermal leishmaniasis (PKDL) are usually extrapolated from those for visceral leishmaniasis (VL), but drug pharmacokinetics (PK) can differ due to...

Journal Article
|
Research

Prediction of visceral leishmaniasis development in a highly exposed HIV cohort in Ethiopia based on Leishmania infection markers: results from the PreLeisH study

van Griensven J, van Henten S, Kibret A, Kassa M, Beyene H,  et al.
2024-12-01 • EBioMedicine
2024-12-01 • EBioMedicine

BACKGROUND

Tar...

Journal Article
|
Research

A preliminary indication that HLA-A*03:01 may be associated with visceral leishmaniasis development in people living with HIV in Ethiopia

de Vrij N, Vandoren R, Ramadan K, Van Hul A, Ceulemans A,  et al.
2024-09-30 • PLOS Neglected Tropical Diseases
2024-09-30 • PLOS Neglected Tropical Diseases

Human immunodeficiency virus (HIV) co-infection is a major challenge for visceral leishmaniasis (VL) control, particularly in Ethiopia where the incidence of both pathogens is high. V...

Journal Article
|
Research

Persistent T cell unresponsiveness associated with chronic visceral leishmaniasis in HIV-coinfected patients

de Vrij N, Pollmann J, Rezende AM, Ibarra-Meneses AV, Pham TT,  et al.
2024-05-03 • Communications Biology
2024-05-03 • Communications Biology
A large proportion of HIV-coinfected visceral leishmaniasis (VL-HIV) patients exhibit chronic disease with frequent VL recurrence. However, knowledge on immunological determinants underl...
Journal Article
|
Pre-Print

HLA-A*03:01 is associated with visceral leishmaniasis development in people living with HIV in Ethiopia

de Vrij N, Vandoren R, Ramadan K, Van Hul A, Kassa M,  et al.
2024-02-18 • medRxiv
2024-02-18 • medRxiv
Human immunodeficiency virus (HIV) co-infection is a major challenge for visceral leishmaniasis (VL) control, particularly in Ethiopia where the incidence of both pathogens is high. VL-H...
Journal Article
|
Research

Population pharmacokinetics of a combination of miltefosine and paromomycin in Eastern African children and adults with visceral leishmaniasis

Verrest L, Roseboom IC, Wasunna M, Mbui J, Njenga SN,  et al.
2023-09-20 • Journal of Antimicrobial Chemotherapy
2023-09-20 • Journal of Antimicrobial Chemotherapy
OBJECTIVES
To improve visceral leishmaniasis (VL) treatment in Eastern Africa, 14- and 28-day combination regimens of paromomycin plus allometrically dosed miltefosine were evaluated...
Conference Material
|
Slide Presentation

Efficacy and safety of 14-day treatment with paromomycin and miltefosine for primary visceral leishmaniasis in eastern Africa: non-inferiority trial

Solomos A, Musa AM, Mbui J, Mohammed R, Olobo J,  et al.
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023
Conference Material
|
Poster

Risk factors for mortality among patients with suspected cholera treated in MSF-supported cholera treatment facilities in Bauchi State, Nigeria

Garcia Naranjo A, Chamman K, Gandi AY, Baba Aminu I, Maigari IM,  et al.
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023
Conference Material
|
Abstract

Efficacy and safety of 14-day treatment with paromomycin and miltefosine for primary visceral leishmaniasis in eastern Africa: non-inferiority trial

Solomos A, Musa AM, Mbui J, Mohammed R, Olobo J,  et al.
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023
INTRODUCTION
The parasitic disease visceral leishmaniasis (VL) is most commonly caused by Leishmania donovani in eastern Africa, currently the region with highest burden worldwide. C...
Journal Article
|
Research

Paromomycin and miltefosine combination as an alternative to treat patients with visceral leishmaniasis in Eastern Africa: A randomized, controlled, multicountry trial

Musa AM, Mbui J, Mohammed R, Olobo J, Ritmeijer KKD,  et al.
2022-09-27 • Clinical Infectious Diseases
2022-09-27 • Clinical Infectious Diseases
BACKGROUND
This study aimed to determine whether paromomycin plus miltefosine (PM/MF) is noninferior to sodium stibogluconate plus paromomycin (SSG/PM) for treatment of primary visce...
Journal Article
|
Research

Development and external validation of a clinical prognostic score for death in visceral leishmaniasis patients in a high HIV co-infection burden area in Ethiopia

Abongomera C, Ritmeijer KKD, Vogt F, Buyze J, Mekonnen Z,  et al.
2017-06-05 • PLOS One
2017-06-05 • PLOS One
BACKGROUND
In Ethiopia, case fatality rates among subgroups of visceral leishmaniasis (VL) patients are high. A clinical prognostic score for death in VL patients could contribute to...
Journal Article
|
Research

Leishmania antigenuria to predict initial treatment failure and relapse in visceral leishmaniasis/HIV coinfected patients: an exploratory study nested within a clinical trial in Ethiopia

van Griensven J, Mangesha B, Mekonnen T, Fikre H, Takele Y,  et al.
2018-03-29 • Frontiers in Cellular and Infection Microbiology
2018-03-29 • Frontiers in Cellular and Infection Microbiology
BACKGROUND
Biomarkers predicting the risk of VL treatment failure and relapse in VL/HIV coinfected patients are needed. Nested within a two-site clinical trial in Ethiopia (2011-2015...
Journal Article
|
Research

The risk and predictors of visceral leishmaniasis relapse in HIV co-infected patients in Ethiopia: a retrospective cohort study

Abongomera C, Diro EGJ, Vogt F, Tsoumanis A, Mekonnen Z,  et al.
2017-10-30 • Clinical Infectious Diseases
2017-10-30 • Clinical Infectious Diseases
BACKGROUND
East Africa, where Leishmania donovani is prevalent, faces the highest burden world-wide of visceral leishmaniasis (VL) and human immunodeficiency virus (HIV) coinfection...
Journal Article
|
Research

Long-term Clinical Outcomes in Visceral Leishmaniasis-HIV Co-infected Patients during and after Pentamidine Secondary Prophylaxis in Ethiopia: a single-arm clinical trial

Diro EGJ, Ritmeijer KKD, Boelaert M, Alves F, Mohammed R,  et al.
2017-09-13 • Clinical Infectious Diseases
2017-09-13 • Clinical Infectious Diseases
We have conducted a single-arm trial evaluating monthly pentamidine secondary prophylaxis (PSP) to prevent visceral leishmaniasis (VL) relapse in Ethiopian HIV-patients. Outcomes at 12 m...
Journal Article
|
Research

Tuberculosis in Visceral Leishmaniasis-Human Immunodeficiency Virus Coinfection: An Evidence Gap in Improving Patient Outcomes?

van Griensven J, Mohammed R, Ritmeijer KKD, Burza S, Diro EGJ
2018-03-16 • Open Forum Infectious Diseases
2018-03-16 • Open Forum Infectious Diseases
Visceral leishmaniasis (VL)-human immunodeficiency virus (HIV) coinfection remains a major problem in Ethiopia, India, and Brazil. Tuberculosis (TB), a treatable factor, could contribute...